IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms

被引:79
作者
De Bruyne, Elke [1 ]
Bos, Tomas J. [1 ]
Schuit, Frans [2 ]
Van Valckenborgh, Els [1 ]
Menu, Eline [1 ]
Thorrez, Lieven [2 ]
Atadja, Peter [3 ]
Jernberg-Wiklund, Helena [4 ]
Vanderkerken, Karin [1 ]
机构
[1] Vrije Univ Brussel, Dept Hematol & Immunol, B-1090 Brussels, Belgium
[2] Katholieke Univ Leuven, Dept Mol Cell Biol, Louvain, Belgium
[3] Novartis Inst Biomed Res Cambridge, Cambridge, MA USA
[4] Uppsala Univ, Rudbeck Lab, Dept Genet & Pathol, Uppsala, Sweden
基金
瑞典研究理事会;
关键词
PROTEASOME INHIBITOR BORTEZOMIB; RECEPTOR TYROSINE KINASE; GROWTH-FACTOR; BCL-2; FAMILY; CELL-LINES; HISTONE MODIFICATIONS; DNA METHYLATION; CYCLOLIGNAN PPP; IN-VITRO; APOPTOSIS;
D O I
10.1182/blood-2009-07-232801
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Insulin-like growth factor-1 (IGF-1) is an important growth and survival factor in multiple myeloma (MM). Here, we demonstrate that IGF-1 induces significant down-regulation of the proapoptotic BH3-only protein Bim in MM cells. Reduced Bim levels by RNA interference (RNAi) protected cells from drug-induced cell death. The IGF-1-mediated down-regulation of Bim was the result of (1) reduced transcription by activation of the Akt pathway and inactivation of the transcription factor FoxO3a, (2) increased proteasome-mediated degradation of the Bim extra-long protein by activation of the mitogen-activated protein kinase pathway, and (3) epigenetic regulation of both the Bim and the FoxO3a promoter. Treatment of cells with the histone deacetylase inhibitor LBH589 resulted in a clear up-regulation in the expression of Bim. Furthermore, the methylation inhibitor 5-aza-2'deoxycytidine (decitabine) significantly increased the effects of LBH589. On IGF-1 treatment, the Bim promoter region was found to be unmethylated, whereas chromatin immunoprecipitation analysis of the IGF-1-treated cells showed both a reduced histone H3 tail Lys9 (H3K9) acetylation and an increased H3K9 dimethylation, which contributed actively to its silencing. These data identify a new mechanism in the IGF-1-dependent survival of MM cells and emphasize the need for IGF-1-targeted drug therapy. (Blood. 2010;115:2430-2440)
引用
收藏
页码:2430 / 2440
页数:11
相关论文
共 54 条
  • [21] KARPAS A, 1982, LANCET, V1, P931
  • [22] 2 DISTINCT HUMAN MYELOMA CELL-LINES ORIGINATING FROM ONE PATIENT WITH MYELOMA
    KATAGIRI, S
    YONEZAWA, T
    KUYAMA, J
    KANAYAMA, Y
    NISHIDA, K
    ABE, T
    TAMAKI, T
    OHNISHI, M
    TARUI, S
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1985, 36 (02) : 241 - 246
  • [23] DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines
    Kawamoto, Ken
    Hirata, Hiroshi
    Kikuno, Nobuyuki
    Tanaka, Yuichiro
    Nakagawa, Masayuki
    Dahiya, Rajvir
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2008, 123 (03) : 535 - 542
  • [24] Involvement of BH3-only proteins in hematologic malignancies
    Kuroda, Junya
    Taniwaki, Masafumi
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2009, 71 (02) : 89 - 101
  • [25] Molecular characterization of human multiple myeloma cell lines by integrative genomics: Insights into the biology of the disease
    Lombardi, Luigia
    Poretti, Giulia
    Mattioli, Michela
    Fabris, Sonia
    Agnelli, Luca
    Bicciato, Silvio
    Kwee, Ivo
    Rinaldi, Andrea
    Ronchetti, Domenica
    Verdelli, Donata
    Lambertenghi-Deliliers, Giorgio
    Bertoni, Francesco
    Neri, Antonino
    [J]. GENES CHROMOSOMES & CANCER, 2007, 46 (03) : 226 - 238
  • [26] Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function
    Luciano, F
    Jacquel, A
    Colosetti, P
    Herrant, M
    Cagnol, S
    Pages, G
    Auberger, P
    [J]. ONCOGENE, 2003, 22 (43) : 6785 - 6793
  • [27] The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance
    Maiso, Patricia
    Carvajal-Vergara, Xonia
    Ocio, Enrique M.
    Lopez-Perez, Ricardo
    Mateo, Gema
    Gutierrez, Norma
    Atadja, Peter
    Pandiella, Atanasio
    San Miguel, Jesus F.
    [J]. CANCER RESEARCH, 2006, 66 (11) : 5781 - 5789
  • [28] The key to development: interpreting the histone code?
    Margueron, R
    Trojer, P
    Reinberg, D
    [J]. CURRENT OPINION IN GENETICS & DEVELOPMENT, 2005, 15 (02) : 163 - 176
  • [29] Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model
    Menu, E
    Jernberg-Wiklund, H
    Stromberg, T
    De Raeve, H
    Girnita, L
    Larsson, O
    Axelson, M
    Asosingh, K
    Nilsson, K
    Van Camp, B
    Vanderkerken, K
    [J]. BLOOD, 2006, 107 (02) : 655 - 660
  • [30] Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model
    Menu, E
    Kooijman, R
    Van Valckenborgh, E
    Asosingh, K
    Bakkus, M
    Van Camp, B
    Vanderkerken, K
    [J]. BRITISH JOURNAL OF CANCER, 2004, 90 (05) : 1076 - 1083